Revance Therapeutics Inc RVNC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
30.00UNCH (UNCH)
Volume
8,143
Close
30.00UNCH (UNCH)
Volume
297,889
52 week range
20.74 - 34.62

...

Loading . . .
  • Open30.50
  • Day High30.50
  • Day Low29.80
  • Prev Close30.00
  • 52 Week High34.62
  • 52 Week High Date09/16/20
  • 52 Week Low20.74
  • 52 Week Low Date06/15/20

Key Stats

  • Market Cap2.146B
  • Shares Out71.53M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change5.86

KEY STATS

  • Open30.50
  • Day High30.50
  • Day Low29.80
  • Prev Close30.00
  • 52 Week High34.62
  • 52 Week High Date09/16/20
  • 52 Week Low20.74
  • 52 Week Low Date06/15/20
  • Market Cap2.146B
  • Shares Out71.53M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change5.86

RATIOS/PROFITABILITY

  • EPS (TTM)-4.77
  • P/E (TTM)-6.29
  • Fwd P/E (NTM)-7.32
  • EBITDA (MRQ)-268.462M
  • ROE (MRQ)-105.60%
  • Revenue (MRQ)28.57M
  • Gross Margin (MRQ)68.54%
  • Net Margin (MRQ)-1,021.48%
  • Debt To Equity (MRQ)114.51%

EVENTS

  • Earnings Date08/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Revance Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and...
Angus Russell
Non-Executive Chairman
Mark Foley
President
Abhay Joshi Ph.D.
Chief Operating Officer
Tobin Schilke
Chief Financial Officer
Address
1222 Demonbreun Street, Suite 1001
Nashville, TN
37203
United States

Top Peers

SYMBOLLASTCHG%CHG
MORF
Morphic Holding Inc
64.99+1.83+2.90%
MCRB
Seres Therapeutics Inc
20.66+0.12+0.58%
MYOV
Myovant Sciences Ltd
21.78-0.82-3.63%
PRTA
Prothena Corporation PLC
47.65+2.56+5.68%
ZNTL
Zentalis Pharmaceuticals Inc
56.04-0.12-0.21%